198 related articles for article (PubMed ID: 24604835)
1. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.
Orme LM; Babl FE; Barnes C; Barnett P; Donath S; Ashley DM
Pediatr Blood Cancer; 2014 Aug; 61(8):1427-33. PubMed ID: 24604835
[TBL] [Abstract][Full Text] [Related]
2. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences.
Sung L; Feldman BM; Schwamborn G; Paczesny D; Cochrane A; Greenberg ML; Maloney AM; Hendershot EI; Naqvi A; Barrera M; Llewellyn-Thomas HA
J Clin Oncol; 2004 Oct; 22(19):3922-9. PubMed ID: 15459214
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
[TBL] [Abstract][Full Text] [Related]
4. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
Mullen CA; Petropoulos D; Roberts WM; Rytting M; Zipf T; Chan KW; Culbert SJ; Danielson M; Jeha SS; Kuttesch JF; Rolston KV
Cancer; 1999 Jul; 86(1):126-34. PubMed ID: 10391572
[TBL] [Abstract][Full Text] [Related]
5. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients.
Sarashina T; Kobayashi R; Yoshida M; Toriumi N; Suzuki D; Sano H; Azuma H
Pediatr Blood Cancer; 2014 Nov; 61(11):1992-5. PubMed ID: 25130289
[TBL] [Abstract][Full Text] [Related]
7. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
[TBL] [Abstract][Full Text] [Related]
8. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
Paganini H; Gómez S; Ruvinsky S; Zubizarreta P; Latella A; Fraquelli L; Iturres AS; Casimir L; Debbag R
Cancer; 2003 Apr; 97(7):1775-80. PubMed ID: 12655535
[TBL] [Abstract][Full Text] [Related]
9. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
10. Advances in management of low-risk febrile neutropenia.
Teuffel O; Sung L
Curr Opin Pediatr; 2012 Feb; 24(1):40-5. PubMed ID: 22037219
[TBL] [Abstract][Full Text] [Related]
11. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
[TBL] [Abstract][Full Text] [Related]
12. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer.
Quezada G; Sunderland T; Chan KW; Rolston K; Mullen CA
Pediatr Blood Cancer; 2007 Mar; 48(3):273-7. PubMed ID: 16435377
[TBL] [Abstract][Full Text] [Related]
13. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
Hidalgo M; Hornedo J; Lumbreras C; Trigo JM; Colomer R; Perea S; Gómez C; Ruiz A; García-Carbonero R; Cortés-Funes H
Cancer; 1999 Jan; 85(1):213-9. PubMed ID: 9921995
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer.
Aquino VM; Herrera L; Sandler ES; Buchanan GR
Cancer; 2000 Apr; 88(7):1710-4. PubMed ID: 10738231
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
[TBL] [Abstract][Full Text] [Related]
16. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
17. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
[TBL] [Abstract][Full Text] [Related]
18. Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia.
Sung L; Alibhai SM; Ethier MC; Teuffel O; Cheng S; Fisman D; Regier DA
J Clin Epidemiol; 2012 Jun; 65(6):627-34. PubMed ID: 22424607
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
20. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis.
Lucas KG; Brown AE; Armstrong D; Chapman D; Heller G
Cancer; 1996 Feb; 77(4):791-8. PubMed ID: 8616774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
